Medline Inc. (MDLN) Stock Analysis and Metrics

Medline

NASDAQ: MDLN

$38.76 ▲ +1.13 (+3.00%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap31.71 Bn

P/E56.52

P/S4.19

Div. Yield0.00

Total Debt (Qtr)12.57 Bn

Revenue Growth (1y) (Qtr)10.66

Add ratio to table…

About

Medline Inc. is the largest provider of medical surgical products and supply chain solutions serving all points of care based on total net sales of medical surgical products. The company was founded in 1966 and delivers mission critical products used daily across hospitals, surgery centers, physician offices, and post acute facilities. Medline’s mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. The company operates a differentiated distribution network of 70 global distribution centers, warehouses, cross docks, and transship facilities, 45 of which are in the United States. It provides next day delivery to 95% of its U. S. customer base. Medline utilizes artificial intelligence and robotics technology in over 26,000,000 square feet of warehouse space in the United States. It maintains a fleet of more than 2,100 MedTrans trucks.

Medline generates revenue primarily through the sale of approximately 335,000 medical surgical products including surgical and procedural kits, gloves, protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Revenue also comes from supply chain optimization services such as consulting, outsourced warehouse and technology management, put away ready packaging, third party logistics, inventory rationalization, and route planning. The company distributes its products through its own fleet of MedTrans trucks and a network of global distribution facilities.

The company operates through two reportable segments Medline Brand and Supply Chain Solutions.

• Medline Brand offers approximately 190,000 medical surgical products organized into three categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. Front Line Care provides wound care, exam gloves, skin care, incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Surgical Solutions offers operating room and perioperative items such as surgical procedure trays, drapes, gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon gloves, procedure kits, and orthopedic implants. Laboratory and Diagnostics delivers point of care testing, analyzers, instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products.

• Supply Chain Solutions provides approximately 145,000 medical surgical products sourced from over 1,300 third party suppliers including leading national brands. It offers supply chain optimization services such as consulting engagements, outsourced warehouse and technology management, put away ready packaging, third party logistics, inventory rationalization, and route planning.

Medline holds a leading position in the medical surgical market due to its vertical integration as both a manufacturer and distributor, its Prime Vendor model, and a differentiated distribution network. The company competes with other large medical surgical manufacturers and distributors such as McKesson, Cardinal Health, Owens & Minor, and Henry Schein. Medline’s competitive advantages include its broad proprietary product portfolio, scale that enables lower prices and better service levels, and a high Prime Vendor retention rate exceeding 98% over the past five years.

Medline serves hospitals, surgery centers, physician offices, post acute facilities, and other health care providers across the United States and internationally. The company’s customers include acute care centers, ambulatory surgery centers, clinics, and long term care facilities. While specific customer names are not disclosed, the base consists of diverse health care institutions that rely on Medline for medical surgical supplies and supply chain solutions.

Investment Thesis

▲ Bull case

Medline's strategic expansion into international markets through the Prime Vendor agreement with Mohawk Medbuy in Canada represents a significant growth catalyst beyond its established U.S. dominance, leveraging its proven supply chain model to capture untapped demand in a healthcare system with increasing pressure to optimize costs and improve service reliability, while the stockless distribution model and customized low-unit quantity delivery directly to care sites enhance hospital operational efficiency and create sticky, long-term revenue streams that are less susceptible to short-term market fluctuations. This first-of-its-kind agreement outside the U.S. validates the scalability of Medline's Prime Vendor approach, which already drives visibility into customer purchasing patterns and demand dynamics in the U.S., enabling proactive inventory management and industry-leading service levels that deepen customer relationships and reduce churn risk, positioning the company to replicate this success across other international markets as healthcare providers globally seek integrated, responsive supply chain partners.
The company's sustained investment in next-generation automation technologies—including the Symbotic AI-powered robotics system pilot slated for 2027, the Pick Pack Pro™ fulfillment system for health plan orders, and the expanding AutoStore network now at 24 installations nationwide—creates a structural advantage in fulfillment speed, accuracy, and scalability that directly addresses the intense seasonal spikes in health plan product demand and growing customer expectations for direct-to-home delivery, while simultaneously improving labor efficiency and reducing operational costs per unit handled, which is critical as Medline serves more than 45,000 employees across 100+ countries and operates 45 U.S. distribution centers supporting next-day delivery to 95% of customers. These technologies are not incremental upgrades but foundational shifts that transform Medline from a traditional distributor into a technology-enabled supply chain orchestrator, allowing it to capture share in high-growth segments like Medicare-administered health plans and aging-in-place care while reinforcing its resilience against disruptions through intelligent inventory optimization and real-time demand responsiveness.
Medline's recent operational milestones—including the groundbreaking for a new 1.2 million sq. ft. distribution center in Midlothian, Texas, slated for Q2 2027 operation, and its recognition via Healthcare Industry Resiliency Collaborative (HIRC) awards for Supplier Partnership and Resiliency—demonstrate a disciplined, customer-centric growth strategy rooted in physical infrastructure expansion and supply chain excellence, where the new Texas facility complements its existing Wilmer location to strengthen Dallas-Fort Worth market coverage amid rising regional demand, and the HIRC accolades validate its ability to build durable, collaborative relationships with healthcare providers through shared problem-solving and contingency readiness, which are intangible assets that translate into higher contract renewal rates, pricing power, and resistance to competitive displacement in an industry where trust and reliability are paramount.

Medline's strategic expansion into international markets through the Prime Vendor agreement with Mohawk Medbuy in Canada represents a significant growth catalyst beyond its established U.S. dominance, leveraging its proven supply chain model to capture untapped demand in a healthcare system with increasing pressure to optimize costs and improve service reliability, while the stockless distribution model and customized low-unit quantity delivery directly to care sites enhance hospital operational efficiency and create sticky, long-term revenue streams that are less susceptible to short-term market fluctuations. This first-of-its-kind agreement outside the U.S. validates the scalability of Medline's Prime Vendor approach, which already drives visibility into customer purchasing patterns and demand dynamics in the U.S., enabling proactive inventory management and industry-leading service levels that deepen customer relationships and reduce churn risk, positioning the company to replicate this success across other international markets as healthcare providers globally seek integrated, responsive supply chain partners.
The company's sustained investment in next-generation automation technologies—including the Symbotic AI-powered robotics system pilot slated for 2027, the Pick Pack Pro™ fulfillment system for health plan orders, and the expanding AutoStore network now at 24 installations nationwide—creates a structural advantage in fulfillment speed, accuracy, and scalability that directly addresses the intense seasonal spikes in health plan product demand and growing customer expectations for direct-to-home delivery, while simultaneously improving labor efficiency and reducing operational costs per unit handled, which is critical as Medline serves more than 45,000 employees across 100+ countries and operates 45 U.S. distribution centers supporting next-day delivery to 95% of customers. These technologies are not incremental upgrades but foundational shifts that transform Medline from a traditional distributor into a technology-enabled supply chain orchestrator, allowing it to capture share in high-growth segments like Medicare-administered health plans and aging-in-place care while reinforcing its resilience against disruptions through intelligent inventory optimization and real-time demand responsiveness.
Medline's recent operational milestones—including the groundbreaking for a new 1.2 million sq. ft. distribution center in Midlothian, Texas, slated for Q2 2027 operation, and its recognition via Healthcare Industry Resiliency Collaborative (HIRC) awards for Supplier Partnership and Resiliency—demonstrate a disciplined, customer-centric growth strategy rooted in physical infrastructure expansion and supply chain excellence, where the new Texas facility complements its existing Wilmer location to strengthen Dallas-Fort Worth market coverage amid rising regional demand, and the HIRC accolades validate its ability to build durable, collaborative relationships with healthcare providers through shared problem-solving and contingency readiness, which are intangible assets that translate into higher contract renewal rates, pricing power, and resistance to competitive displacement in an industry where trust and reliability are paramount.

▼ Bear case

Medline faces escalating regulatory risk from repeated FDA warning letters regarding manufacturing quality violations, including the April 2026 notice about defective syringes used in heart procedures—which led to recalls and complaints of air embolism and biohazard exposure—and the June 2026 letter citing inadequate microbial contamination investigations and cleaning procedure deviations at its ReadyCare Waukegan facility, signaling systemic issues in quality control oversight that could trigger fines, product seizures, or consent decrees if not swiftly remediated, thereby diverting management focus from growth initiatives, increasing compliance costs, and damaging brand reputation among healthcare providers who prioritize patient safety above cost savings, especially given the company's own internal risk assessments were deemed inconsistent with FDA data, suggesting potential blind spots in its quality management culture.
Despite its technological investments, Medline's reliance on a capital-intensive distribution network—evidenced by the new 1.2 million sq. ft. Texas DC and 45 existing U.S. facilities—creates significant fixed-cost leverage in an industry facing persistent pricing pressure from group purchasing organizations (GPOs) and hospital consolidation, where any slowdown in healthcare capital expenditures or shift toward alternative care sites (e.g., ambulatory surgery centers, home health) could underutilize these assets, while the company's dependence on third-party logistics for international expansion (e.g., the Mohawk Medbuy agreement) limits control over service quality and increases vulnerability to local labor disputes, transportation disruptions, or regulatory differences in markets like Canada, where healthcare procurement operates under provincial frameworks that may not mirror U.S. GPO dynamics, potentially delaying ROI on international Prime Vendor deals.
The bullish narrative around Medline's supply chain strength and brand penetration may overlook the commoditization risk in core medical-surgical products, where competitors like Cardinal Health and McKesson offer similar scale and pricing, and the company's growth depends heavily on winning share in low-margin, high-volume categories (e.g., gloves, syringes, OTC items) that are susceptible to private-label competition and reimbursement pressures from Medicare and Medicaid, while its focus on value-added services like kitting (e.g., spay/neuter packs) and custom surgical trays remains a relatively small portion of its ~335,000-product portfolio, meaning that without sustained innovation in higher-margin clinical solutions or differentiated offerings, Medline's long-term profitability could be constrained by the inherent low-margin nature of its core distribution business, especially as healthcare providers increasingly adopt just-in-time inventory models that reduce the need for large safety stocks Medline traditionally provides.

Medline faces escalating regulatory risk from repeated FDA warning letters regarding manufacturing quality violations, including the April 2026 notice about defective syringes used in heart procedures—which led to recalls and complaints of air embolism and biohazard exposure—and the June 2026 letter citing inadequate microbial contamination investigations and cleaning procedure deviations at its ReadyCare Waukegan facility, signaling systemic issues in quality control oversight that could trigger fines, product seizures, or consent decrees if not swiftly remediated, thereby diverting management focus from growth initiatives, increasing compliance costs, and damaging brand reputation among healthcare providers who prioritize patient safety above cost savings, especially given the company's own internal risk assessments were deemed inconsistent with FDA data, suggesting potential blind spots in its quality management culture.
Despite its technological investments, Medline's reliance on a capital-intensive distribution network—evidenced by the new 1.2 million sq. ft. Texas DC and 45 existing U.S. facilities—creates significant fixed-cost leverage in an industry facing persistent pricing pressure from group purchasing organizations (GPOs) and hospital consolidation, where any slowdown in healthcare capital expenditures or shift toward alternative care sites (e.g., ambulatory surgery centers, home health) could underutilize these assets, while the company's dependence on third-party logistics for international expansion (e.g., the Mohawk Medbuy agreement) limits control over service quality and increases vulnerability to local labor disputes, transportation disruptions, or regulatory differences in markets like Canada, where healthcare procurement operates under provincial frameworks that may not mirror U.S. GPO dynamics, potentially delaying ROI on international Prime Vendor deals.
The bullish narrative around Medline's supply chain strength and brand penetration may overlook the commoditization risk in core medical-surgical products, where competitors like Cardinal Health and McKesson offer similar scale and pricing, and the company's growth depends heavily on winning share in low-margin, high-volume categories (e.g., gloves, syringes, OTC items) that are susceptible to private-label competition and reimbursement pressures from Medicare and Medicaid, while its focus on value-added services like kitting (e.g., spay/neuter packs) and custom surgical trays remains a relatively small portion of its ~335,000-product portfolio, meaning that without sustained innovation in higher-margin clinical solutions or differentiated offerings, Medline's long-term profitability could be constrained by the inherent low-margin nature of its core distribution business, especially as healthcare providers increasingly adopt just-in-time inventory models that reduce the need for large safety stocks Medline traditionally provides.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password